Drug Profile
Tovinontrine - Cardurion Pharmaceuticals
Alternative Names: 68722; AF68722; CK1598; CRD-750; IMR-687Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer Enliven Therapeutics
- Class Antianaemics; Heart failure therapies; Imidazoles; Pyrans; Pyrazines; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Phosphodiesterase 9A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic heart failure
- Discontinued Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 31 Mar 2024 Phase-II clinical trials in Chronic heart failure in USA (PO) (NCT06215586)
- 21 Mar 2024 Cardurion Pharmaceuticals initiates a phase II Cycle-1-REF trial for Heart failure (PO, Tablets) as of March 2024 (NCT06215911)
- 30 Jan 2024 Cardurion Pharmaceuticals plans a phase II Cycle-2-PEF trial for Heart failure (PO, Tablet) (NCT06215586)